Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2019 | Story Nikile Ntsababa (Registrar)

The nomination process for the election of two representatives to serve on the UFS Council was finalised on Tuesday, 17 September 2019 – the closing date for nominations.
 
Here are the names of the nominees (listed alphabetically):
 
Representative from the Qwaqwa Campus:
None
 
Other representative:
Mr Christo Dippenaar
Dr Pieter du Toit
Mr Lefa Mabaso
Dr Walter Matli
Mr Zama Sigwebela
 
Please note that no nominations were received for representatives from the Qwaqwa Campus.  Since this scenario is not legislated in the Statute, Institutional Rules, and Convocation Constitution, the Registrar will, after consultation with the President of the Convocation, open another round of nominations for Qwaqwa representatives to Council (with the closing date 8 October 2019) to ensure that the campus is also represented on Council.
 
Convocation and Alumni members from the Qwaqwa Campus are therefore given a second opportunity to nominate one representative from among their members for the Qwaqwa Campus.  All nominations must reach the office of the Registrar no later than 16:30 on Wednesday, 9 October 2019.
 
Every nomination form  shall be signed by four (4) members of the Convocation and shall contain the written acceptance of the nomination by the nominee under his/her signature as well as an abridged CV and a motivation of more or less 200 words.
 
Nominations are to be submitted to:  email: registrar@ufs.ac.za or delivered by hand to Nikile Ntsababa, Main Building, Room 51, Bloemfontein Campus.
 
Kindly take note that late or incomplete nominations will not be accepted or considered.
 
Further information regarding the election process will follow in due course.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept